** Vaccine maker Moderna's MRNA.O shares fall 2.2% to $31.30 premarket
** Co reports Q4 loss of $2.91/share vs analyst est. of loss of $2.68/share, as per data compiled by LSEG
** MRNA posts Q4 revenue of $966 million, beating analysts' est. of $942.84 million
** Co says the decrease was mostly due to the earlier launch of its updated COVID-19 vaccine in the U.S., which shifted sales into the third quarter, but also due to lower international sales
** Stock fell ~67% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。